Kaleo Pharma

NEWS

Pictured: Doorway at the FTC building in Washingto

Policy

Three Companies Relent to FTC Demands, Delist Patents from FDA’s Orange Book

GSK withdrew three patents related to its asthma inhalers while Impax delisted both of its patents for Adrenaclick and Kaléo delisted eight patents covering Auvi-Q—the companies’ respective epinephrine auto-injectors.

December 22, 2023

2 min read

Kate Goodwin

BioCapital

Senators Question Kaleo Over 680% Price Hike of Naloxone Injector Evzio

February 10, 2017

1 min read

IN THE PRESS

Business

Intelliject, Inc. Announces $15 Million Debt Financing to Accelerate Targeted Pipeline Development

May 30, 2012

3 min read

JOBS